Skip to main content
. 2021 Apr 30;3(4):546–554.e1. doi: 10.1016/j.xkme.2021.02.013

Table 1.

Baseline Characteristics by Quartiles of Urinary Creatinine

N Q1
Q2
Q3
Q4
Total
590 590 590 590 2,360
Range, mg/dL <75 75-112 113-161 ≥162
Randomization arm
 Standard 289 (49%) 286 (49%) 285 (48%) 300 (51%) 1,160 (49%)
 Intensive 301 (51%) 304 (51%) 305 (52%) 290 (49%) 1,200 (51%)
Age, y 75 ± 9 74 ± 9 73 ± 9 71 ± 9 73 ± 9
Female sex 307 (52%) 247 (42%) 195 (33%) 192 (33%) 941 (40%)
Race/ethnicity
 Non-Hispanic White 428 (73%) 398 (68%) 392 (66%) 340 (58%) 1,558 (66%)
 Non-Hispanic Black 114 (19%) 134 (23%) 147 (25%) 210 (36%) 605 (26%)
 Hispanic 35 (6%) 52 (9%) 36 (6%) 36 (6%) 159 (7%)
 Other 13 (2%) 6 (1%) 15 (3%) 4 (1%) 38 (2%)
Smoking
 Never 273 (46%) 271 (46%) 250 (42%) 270 (46%) 1,064 (45%)
 Former 279 (47%) 258 (44%) 289 (49%) 261 (44%) 1,087 (46%)
 Current 38 (6%) 61 (10%) 51 (9%) 59 (10%) 209 (9%)
BMI, kg/m2 28.8 ± 5.8 29.4 ± 6.1 29.8 ± 5.7 30.2 ± 5.9 29.5 ± 5.9
History of cardiovascular disease 130 (22%) 167 (28%) 159 (27%) 141 (24%) 597 (25%)
History of heart failure 51 (9%) 34 (6%) 31 (5%) 35 (6%) 151 (6%)
Systolic BP, mm Hg 142 ± 17 140 ± 16 138 ± 15 138 ± 16 139 ± 16
Diastolic BP, mm Hg 73 ± 12 73 ± 12 74 ± 12 76 ± 13 74 ± 12
No. of antihypertensive medications
 0 26 (4%) 27 (5%) 25 (4%) 19 (3%) 97 (4%)
 1 115 (20%) 115 (20%) 145 (25%) 149 (25%) 524 (22%)
 2 202 (34%) 232 (39%) 212 (36%) 215 (36%) 861 (37%)
 3 187 (32%) 162 (28%) 166 (28%) 163 (28%) 678 (29%)
 ≥4 60 (10%) 54 (9%) 42 (7%) 44 (8%) 200 (9%)
RAAS-I 362 (61%) 374 (63%) 377 (64%) 354 (60%) 1,467 (62%)
Diuretics 373 (63%) 322 (55%) 302 (51%) 294 (50%) 1,291 (55%)
Total cholesterol, mg/dL 186 ± 39 184 ± 42 182 ± 40 183 ± 41 184 ± 41
LDL cholesterol, mg/dL 105 ± 33 106 ± 34 106 ± 34 107 ± 36 106 ± 35
HDL cholesterol, mg/dL 56 ± 15 53 ± 15 51 ± 14 50 ± 13 52 ± 14
Median serum creatinine, mg/dL 1.30 [1.11-1.57] 1.33 [1.16-1.58] 1.35 [1.19-1.60] 1.36 [1.20-1.58] 1.34 [1.17-1.59]
Median serum cystatin C, mg/L 1.45 [1.27-1.79] 1.45 [1.28-1.74] 1.39 [1.25-1.66] 1.36 [1.23-1.56] 1.41 [1.26-1.69]
eGFR, mL/min/1.73 m2 44 ± 11 44 ± 11 46 ± 10 48 ± 9 46 ± 11
Median urinary creatinine, mg/dL 51 [37-65] 94 [85-103] 133 [121-148] 206 [180-250] 112 [75-161]
β2-microglobulin, ng/mL 87 [30-355] 132 [48-461] 90 [41-299] 102 [28-244] 101 [36-325]
α1-microglobulin, mg/L 8 [4-14] 15 [8-25] 15 [9-28] 21 [10-35] 14 [7-25]
YKL-40, ng/mL 269 [113-689] 448 [188-1,073] 603 [304-1,144] 1,080 [561-2,135] 555 [223-1,267]
IL-18, ng/mL 13 [8-23] 26 [17-42] 37 [24-59] 60 [39-108] 31 [17-57]
UMOD, ng/mL 4 [3-6] 6 [5-9] 8 [6-11] 9 [6-12] 7 [4-10]
MCP-1, pg/mL 64 [32-102] 149 [102-242] 221 [152-331] 389 [269-602] 185 [94-331]
KIM-1, pg/mL 276 [110-520] 717 [424-1,094] 1,080 [702-1,643] 1,902 [1,266-3,043] 872 [411-1,618]
NGAL, ng/mL 17 [9-39] 26 [15-56] 31 [18-60] 39 [23-77] 28 [15-60]
Urinary albumin, mg/L 11 [4-35] 14 [7-57] 17 [8-56] 24 [13-67] 16 [8-52]

Note: Data presented as mean ± standard deviation, number (percent), or median [interquartile range].

Abbreviations BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Q, quartile; RAAS-I, renin-angiotensin-aldosterone system inhibitor; IL-18, interleukin 18; KIM-1, kidney injury marker-1; MCP-1, monocyte chemoattractant protein 1; NGAL, neutrophil gelatinase-associated lipocalin; UMOD, uromodulin; YKL-40, chitinase-3-like protein-1.